|3.||Hepatocellular Carcinoma (Hepatoma)
|5.||Liver Diseases (Liver Disease)
|1.||Zeuzem, Stefan: 121 articles (11/2015 - 10/2002)|
|2.||Kumada, Hiromitsu: 76 articles (07/2015 - 01/2002)|
|3.||McHutchison, John G: 62 articles (07/2015 - 03/2002)|
|4.||Sarrazin, Christoph: 57 articles (11/2015 - 12/2002)|
|5.||Shiffman, Mitchell L: 57 articles (10/2014 - 09/2002)|
|6.||Marcellin, Patrick: 55 articles (07/2015 - 01/2002)|
|7.||Yu, Ming-Lung: 54 articles (10/2015 - 01/2002)|
|8.||Berg, Thomas: 54 articles (10/2015 - 12/2002)|
|9.||Chuang, Wan-Long: 53 articles (10/2015 - 01/2002)|
|10.||Suzuki, Fumitaka: 51 articles (07/2015 - 01/2002)|
01/01/1994 - "We conclude that repeated interferon alpha-2b treatment courses are probably beneficial in patients with chronic hepatitis C who show a non-sustained response to interferon, since studies on the natural course of chronic hepatitis C have indicated a progressive deterioration of the histological picture in many untreated patients, most marked among those with CAH."
04/01/2003 - "The best treatment for chronic hepatitis C patients who do not respond to interferon is still unknown. "
09/01/1998 - "Short courses (6 months) of interferon (IFN) are highly cost-effective in patients with histologically mild chronic hepatitis C. "
04/01/1998 - "The best results in terms of clinical remission in chronic hepatitis C are achieved by interferon (IFN)-alpha treatment. "
01/01/1998 - "In an attempt to determine the best therapeutic protocol for the treatment of chronic hepatitis C with interferon (IFN), we reported our experience comparing the efficacy of IFN at the usual dose and duration, i.e. "
|2.||Ribavirin (Virazole)FDA LinkGeneric
03/01/2013 - "Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis. "
10/01/2006 - "These results show that combination therapy with Peg-IFNalpha2b plus ribavirin is highly efficacious in hemophiliacs with chronic hepatitis C."
01/01/2002 - "Combination therapy with subcutaneous interferon-alpha-2b [3 million units (MU) three times per week] plus oral ribavirin (1000 to 1200 mg/day) has proven effective in several well designed trials of 24 to 48 weeks' duration in adult patients with compensated chronic hepatitis C. "
01/01/2003 - "In conclusion, combination therapy comprising subcutaneous peginterferon-alpha-2a (40kD) and oral ribavirin is an important new treatment option for chronic hepatitis C. "
07/01/2013 - "The long-term outcome, including APRI, of chronic hepatitis C patients treated successfully with PegIFN/ribavirin and followed for a mean of 5.7 years is favorable. "
|3.||Interferon-alpha (Interferon Alfa)FDA Link
02/01/1999 - "Interferon-alfa treatment is the only licensed therapy for chronic hepatitis C until now, but an efficacy of such treatment is highly variable. "
04/01/1996 - "Some patients with chronic hepatitis C are very sensitive to alpha interferon and can be successfully treated with low doses. "
02/01/1996 - "Alpha interferon (IFN-alpha) is, to date, the only treatment with proven efficacy in patients with chronic hepatitis C. "
02/01/1993 - "Interferon-alpha (IFN-alpha) has proven useful in the treatment of chronic hepatitis C, but a relapse in response is frequently observed. "
09/01/1992 - "Interferon-alpha therapy is of proven efficacy in chronic hepatitis C, but it is not universally effective and may be associated with intolerable side effects. "
|4.||RNA (Ribonucleic Acid)IBA
03/28/2010 - "Short-term PEG-IFN alpha2a monotherapy is highly effective for chronic hepatitis C patients who have low pretreatment HCV RNA load and exhibit IVR."
09/01/2007 - "There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA. "
01/01/2006 - "Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load."
07/01/2005 - "RIB administration preceding combined treatment of RIB with IFN was more effective in Th2 cell expansion than the usual combined treatment of IFN with RIB and led to a relatively early virological clearance in chronic hepatitis C patients with genotype 1b and a high HCV RNA level."
08/01/2000 - "The twice-a-day administration of IFN accelerated the clearance of HCV RNA from serum, leading to a more efficient virological response for patients with chronic hepatitis C, but with a high rate of renal toxicity."
01/01/2014 - "Telaprevir-based triple therapy is a highly effective treatment for chronic hepatitis C. "
08/01/2013 - "Telaprevir-based triple therapy is highly effective for chronic hepatitis C. "
12/01/2014 - "This study investigated the relationship between hepatitis C virus (HCV) dynamics and sustained virological response (SVR), as well as the efficacy of an extended treatment with telaprevir-based triple therapy among patients with chronic hepatitis C genotype 1b. "
07/01/2015 - "Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan."
01/01/2015 - "Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C."
|6.||Amantadine (Aman)FDA LinkGeneric
01/01/2004 - "In 1997, it was suggested that amantadine monotherapy could be used successfully to treat patients with chronic hepatitis C who had previously failed IFN alfa therapy, but ensuing studies could not support these findings. "
10/01/2000 - "In conclusion, combination therapy IFN-alpha plus amantadine is as effective as IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C."
10/01/2000 - "Although the antiviral effects of amantadine sulphate (1-aminoadamantan sulphate) have not been characterized for the hepatitis C virus (HCV), previous pilot studies have suggested promising results in patients with chronic hepatitis C. "
04/01/1999 - "However, few studies about efficacy of amantadine in chronic hepatitis C are available with controversial results. "
06/01/2003 - "The antiviral efficacy of amantadine in patients with chronic hepatitis C is controversial. "
|7.||Alanine Transaminase (SGPT)IBA
09/01/1995 - "To evaluate the efficacy of more aggressive treatment regimens, we have conducted a randomized trial in 174 patients with chronic hepatitis C using three different schedules: (1) 12-month treatment starting with 6 MU/ three times a week and decreasing the dose on the basis of serum alanine transaminase (ALT) activities (group A: 59 cases); (2) fixed dose of 3 MU three times a week for 12 months (Group B: 61 cases), (3) fixed dose of 6 MU three times of week for 6 months (Group C: 54 cases). "
01/01/2014 - "The purpose of this study was to investigate the incidence and demographic/clinical factors of alanine aminotransferase (ALT) abnormalities at the end of treatment (EOT) in chronic hepatitis C (CHC) patients with sustained virologic response (SVR). "
12/01/2004 - "Patients with chronic hepatitis C and persistently normal alanine aminotransferase (ALT) levels have been routinely excluded from large randomized treatment trials; consequently, the efficacy and safety of antiviral therapy in this population are unknown. "
12/01/2004 - "The aim of the present study was to compare viral kinetics between patients with chronic hepatitis C and persistently normal alanine aminotransferase (ALT) levels and those with elevated ALT levels. "
01/01/2002 - "In this prospective open trial 152 patients with biopsy-proven chronic hepatitis C were enrolled, 32 of whom had persistently normal alanine aminotransferase levels (group A). "
|8.||Interferon Alfa-2b (Interferon Alfa 2b)FDA Link
01/01/1993 - "Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C."
11/01/2000 - "A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype."
01/01/2000 - "The aim of this study was to evaluate the most appropriate therapeutic protocol for patients with chronic hepatitis C not responding to a previous course of recombinant interferon alpha-2b (rIFN). "
07/01/1998 - "Seventy patients with chronic hepatitis C who participated in two trials of recombinant interferon alpha 2b treatment were studied. "
09/01/1997 - "We performed an independent meta-analysis of all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C. "
07/01/2000 - "Several pretreatment factors have been reported to be useful in predicting patients with a high probability for a sustained response to IFN-alpha treatment, however, predictors of the efficacy of interferon-beta treatment in chronic hepatitis C have not been fully assessed. "
04/01/1998 - "However, due to the high cost of beta interferon, this high-dose schedule would probably not be cost-effective in the treatment of chronic hepatitis C."
05/01/2003 - "The intravenous administration of interferon-beta may be effective for the treatment of chronic hepatitis C, as is intramuscular interferon-beta. "
04/01/1998 - "The intramuscular use of beta interferon has been tested in the treatment of chronic hepatitis C, but it did not prove effective when the schedule was 3 million units three times a week for six months. "
01/01/2008 - "The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load."
|10.||N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
02/01/2013 - "This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. "
03/15/2015 - "A 55-year-old woman was started on boceprevir (800 mg orally thrice daily) during week 5 of triple therapy for chronic hepatitis C. "
01/01/2015 - "Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia."
01/01/2015 - "Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C."
10/01/2014 - "In untreated genotype 1b chronic hepatitis C patients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy."
05/01/1997 - "In conclusion, this combination treatment was more effective than retreatment with IFN-alpha, alone, in inducing sustained biochemical remission of chronic hepatitis C that was resistant to a previous course of IFN-alpha. "
11/01/1997 - "The aim of this study was to define the efficacy of IFN retreatment in chronic hepatitis C. "
07/01/2004 - "[Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C]."
01/01/2004 - "We assessed the efficacy of IFN retreatment for chronic hepatitis C patients who had a biochemical response (BR) after the first IFN therapy and reelevated ALT during follow up, by a case control study. "
01/01/1995 - "The aim of our study was to assess IFN-alpha retreatment in chronic hepatitis C. "
|2.||Renal Dialysis (Hemodialysis)
01/01/2011 - "Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. "
08/01/2015 - "The aim of the study was to evaluate the association between SNPs near the IL28B gene and response to the treatment of chronic hepatitis C in hemodialysis patients. "
01/01/2009 - "At the end of the study, peg-IFN-alpha-2a treatment of patients with chronic hepatitis C on maintenance hemodialysis may improve prognosis and their quality of life."
11/01/2001 - "Five maintenance hemodialysis patients with chronic hepatitis C (4 men and 1 woman) were enrolled in this study. "
11/01/2001 - "Eleven hemodialysis patients with chronic hepatitis C that received IFNalpha treatment were included in this study. "
04/01/2011 - "The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. "
03/01/2011 - "Delayed viral clearance of chronic hepatitis C in patients after treatment failure."
01/01/2011 - "The aim of this study was to use TE to evaluate whether patients with sustained virological response (SVR) have lower liver stiffness than patients with non-SVR after treatment for chronic hepatitis C (CHC). "
01/01/2005 - "In this study, sCD30 serum levels in 25 patients with chronic hepatitis C, before and after treatment with IFN-2alpha, were measured. "
09/21/2015 - "To evaluate the changes of shear-wave velocity (Vs) by acoustic radiation force impulse after treatment in chronic hepatitis C. "
11/01/2008 - "Clinical trials of patients with chronic hepatitis C and healthy, functioning kidney grafts are rare because of the inherent dangers of graft rejection. "
03/01/2004 - "The objective of our study was to analyze the United Network for Organ Sharing liver transplant database to compare patient and graft survival in recipients transplanted for chronic hepatitis C who received a living donor organ and deceased donor organ between 1999 and 2002. "
12/27/1996 - "The aim of the current study was to analyze the causes of graft loss following OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large university program. "
06/28/2015 - "Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?"
06/01/2014 - "Recurrence of chronic hepatitis C on liver graft was classified according to Metavir score. "
|5.||Transplantation (Transplant Recipients)
10/01/2011 - "This study was carried out to evaluate the outcome of autologous bone marrow-derived hepatocytes transplantation in patients with end-stage liver cell failure due to chronic hepatitis C. "
01/01/2015 - "Long-term pegylated interferon-α-2a treatment for chronic hepatitis C in an elderly renal transplant recipient: case report and literature review."
02/01/2013 - "Management of the transplant recipient with chronic hepatitis C."
12/01/2011 - "A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C."
05/01/2009 - "Eight renal transplant recipients with chronic hepatitis C were recruited. "